[{"id":"731a7f94-ad73-4cc1-96c6-298d3b4cf270","acronym":"ZEBRA","url":"https://clinicaltrials.gov/study/NCT05635162","created_at":"2022-12-02T15:56:31.374Z","updated_at":"2024-07-02T16:34:26.777Z","phase":"Phase 2","brief_title":"Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma","source_id_and_acronym":"NCT05635162 - ZEBRA","lead_sponsor":"University College, London","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/17/2024","start_date":" 05/17/2024","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-06-12"},{"id":"fa4c40ce-a874-4bf2-93ea-d0fcb6f11e59","acronym":"","url":"https://clinicaltrials.gov/study/NCT04189757","created_at":"2021-01-18T20:25:19.472Z","updated_at":"2024-07-02T16:35:05.208Z","phase":"Phase 2","brief_title":"Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma","source_id_and_acronym":"NCT04189757","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/07/2020","start_date":" 08/07/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-08"},{"id":"08b82509-fbbd-4719-b2fe-d7db759f217f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529069","created_at":"2022-09-06T17:03:18.330Z","updated_at":"2024-07-02T16:35:07.866Z","phase":"Phase 2","brief_title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","source_id_and_acronym":"NCT05529069","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification","tags":["TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 04/28/2027","primary_completion_date":" 04/28/2027","study_txt":" Completion: 04/28/2027","study_completion_date":" 04/28/2027","last_update_posted":"2024-04-24"},{"id":"6d4d812a-6716-4ffb-85fc-6bad93889975","acronym":"","url":"https://clinicaltrials.gov/study/NCT03946878","created_at":"2021-01-18T19:25:54.987Z","updated_at":"2024-07-02T16:35:08.979Z","phase":"Phase 2","brief_title":"Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT03946878","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 02/08/2026","primary_completion_date":" 02/08/2026","study_txt":" Completion: 02/08/2026","study_completion_date":" 02/08/2026","last_update_posted":"2024-04-18"},{"id":"0066169f-eea4-4ffc-bdc0-531deb0491dd","acronym":"CAPITAL","url":"https://clinicaltrials.gov/study/NCT05008055","created_at":"2021-08-17T14:53:09.224Z","updated_at":"2024-07-02T16:35:14.322Z","phase":"Phase 2","brief_title":"Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05008055 - CAPITAL","lead_sponsor":"AstraZeneca","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 08/22/2023","primary_completion_date":" 08/22/2023","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-18"},{"id":"b7e05237-c123-498d-b356-0eff2ae8d36b","acronym":"ACE-LY-308","url":"https://clinicaltrials.gov/study/NCT02972840","created_at":"2021-01-18T14:36:50.624Z","updated_at":"2024-07-02T16:35:15.640Z","phase":"Phase 3","brief_title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","source_id_and_acronym":"NCT02972840 - ACE-LY-308","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 635","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 10/28/2025","primary_completion_date":" 10/28/2025","study_txt":" Completion: 10/28/2025","study_completion_date":" 10/28/2025","last_update_posted":"2024-03-08"},{"id":"7d14cf62-7e9e-43f3-a094-c89f0b0ebda6","acronym":"TrAVeRse","url":"https://clinicaltrials.gov/study/NCT05951959","created_at":"2023-07-20T14:08:45.930Z","updated_at":"2024-07-02T16:35:16.071Z","phase":"Phase 2","brief_title":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","source_id_and_acronym":"NCT05951959 - TrAVeRse","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • BCL2 • CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["TP53 • BCL2 • CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 01/17/2029","primary_completion_date":" 01/17/2029","study_txt":" Completion: 01/17/2029","study_completion_date":" 01/17/2029","last_update_posted":"2024-03-06"},{"id":"9a1bd20f-9971-453e-a407-90e121f47cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697940","created_at":"2021-01-19T20:49:56.659Z","updated_at":"2024-07-02T16:35:20.405Z","phase":"Phase 1/2","brief_title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","source_id_and_acronym":"NCT04697940","lead_sponsor":"Han weidong","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • decitabine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-02-07"},{"id":"fb3a0e68-1b79-487f-9799-50d3dba4e7e2","acronym":"ACE-LY-004","url":"https://clinicaltrials.gov/study/NCT02213926","created_at":"2021-01-18T10:22:24.087Z","updated_at":"2024-07-02T16:35:22.603Z","phase":"Phase 2","brief_title":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","source_id_and_acronym":"NCT02213926 - ACE-LY-004","lead_sponsor":"Acerta Pharma BV","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/02/2015","start_date":" 03/02/2015","primary_txt":" Primary completion: 12/04/2020","primary_completion_date":" 12/04/2020","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-01-23"},{"id":"e5397458-5d87-4f9f-b7a0-005976446ec3","acronym":"V-MIND","url":"https://clinicaltrials.gov/study/NCT05910801","created_at":"2023-06-20T14:07:47.501Z","updated_at":"2024-07-02T16:35:23.016Z","phase":"Phase 2","brief_title":"Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT05910801 - V-MIND","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CD19 • CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)","tags":["CD19 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/04/2024","start_date":" 01/04/2024","primary_txt":" Primary completion: 12/30/2029","primary_completion_date":" 12/30/2029","study_txt":" Completion: 12/30/2030","study_completion_date":" 12/30/2030","last_update_posted":"2024-01-18"},{"id":"a2a1d2f4-d5fe-44f6-9d4b-6fab3db22983","acronym":"","url":"https://clinicaltrials.gov/study/NCT04783415","created_at":"2021-03-05T13:54:58.401Z","updated_at":"2024-07-02T16:35:28.898Z","phase":"Phase 2","brief_title":"Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT04783415","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy) • rituximab biosimilar"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/26/2021","start_date":" 03/26/2021","primary_txt":" Primary completion: 07/31/2022","primary_completion_date":" 07/31/2022","study_txt":" Completion: 09/20/2025","study_completion_date":" 09/20/2025","last_update_posted":"2023-11-17"},{"id":"d6f43bf5-4e79-4d99-b785-9354c5c58f6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014073","created_at":"2023-08-28T14:08:34.962Z","updated_at":"2024-07-02T16:35:37.560Z","phase":"Phase 1/2","brief_title":"TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL","source_id_and_acronym":"NCT06014073","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative","tags":["BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • ET-901"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-09-11"},{"id":"b2a4ea25-8d18-422a-b5fb-b8838e229814","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631912","created_at":"2022-11-30T17:57:35.016Z","updated_at":"2024-07-02T16:35:43.904Z","phase":"Phase 1/2","brief_title":"TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL","source_id_and_acronym":"NCT05631912","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative","tags":["BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2023-07-06"},{"id":"79e6536b-19ce-4949-9d3e-880c5f759980","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932331","created_at":"2021-01-18T19:22:10.688Z","updated_at":"2024-07-02T16:35:53.535Z","phase":"Phase 1/2","brief_title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","source_id_and_acronym":"NCT03932331","lead_sponsor":"AstraZeneca","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 04/29/2020","start_date":" 04/29/2020","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/29/2023","study_completion_date":" 12/29/2023","last_update_posted":"2023-03-10"}]